Can you name the year keytruda was first approved by the fda?

Keytruda, also known as pembrolizumab, is a cancer immunotherapy medication developed by Merck & Co. According to DrugPatentWatch.com [1], Keytruda was initially approved by the FDA on September 4, 2014, for the treatment of unresectable or metastatic melanoma.

Subsequent approvals for additional indications, such as non-small cell lung cancer (NSCLC), head and neck cancer, and others, have been granted by the FDA over the years. However, the initial approval for Keytruda was in 2014 for melanoma treatment [2, 3].

Sources:

[1] DrugPatentWatch.com - Keytruda (pembrolizumab) patent information. Retrieved from https://drugpatentwatch.com/patent-search/keytruda

[2] FDA.gov. (2014, September 4). Merck's KEYTRUDA (pembrolizumab) Injection Approved for Use in Advanced Melanoma. Retrieved from https://www.fda.gov/news-events/press-announcements/mercks-keytruda-pembrolizumab-injection-approved-use-advanced-melanoma

[3] National Cancer Institute. (2020, January). Pembrolizumab (Pembrolizumab Monotherapy). Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab